156 related articles for article (PubMed ID: 36902021)
1. A Novel Homodimer Peptide-Drug Conjugate Improves the Efficacy of HER2-Positive Breast Cancer Therapy.
Liu S; Tian Y; Jiang S; Wang Z
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902021
[TBL] [Abstract][Full Text] [Related]
2. Peptide-Drug Conjugate Targeting Keratin 1 Inhibits Triple-Negative Breast Cancer in Mice.
Ziaei E; Paiva IM; Yao SJ; Sarrami N; Mehinrad P; Lai J; Lavasanifar A; Kaur K
Mol Pharm; 2023 Jul; 20(7):3570-3577. PubMed ID: 37307328
[TBL] [Abstract][Full Text] [Related]
3. A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells.
Song Q; Chuan X; Chen B; He B; Zhang H; Dai W; Wang X; Zhang Q
Drug Deliv; 2016 Jun; 23(5):1734-46. PubMed ID: 25853477
[TBL] [Abstract][Full Text] [Related]
4. An Acid-Sensitive Nanofiber Conjugate Based on a Short Aromatic Peptide for Targeted Delivery of Doxorubicin in Liver Cancer.
Liang J; Guo R; Xuan M; Sun Q; Wu W
Int J Nanomedicine; 2022; 17():2961-2973. PubMed ID: 35818401
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer.
You Y; Xu Z; Chen Y
Drug Deliv; 2018 Nov; 25(1):448-460. PubMed ID: 29405790
[TBL] [Abstract][Full Text] [Related]
6. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer.
Saghaeidehkordi A; Chen S; Yang S; Kaur K
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34063098
[TBL] [Abstract][Full Text] [Related]
8. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.
Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ
J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307
[TBL] [Abstract][Full Text] [Related]
9. Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer.
Sheng Y; You Y; Chen Y
Int J Pharm; 2016 Oct; 512(1):1-13. PubMed ID: 27521706
[TBL] [Abstract][Full Text] [Related]
10. Dual-targeted and controlled release delivery of doxorubicin to breast adenocarcinoma: In vitro and in vivo studies.
Jamshidi Z; Sadat Zavvar T; Ramezani M; Alibolandi M; Hadizadeh F; Abnous K; Taghdisi SM
Int J Pharm; 2022 Jul; 623():121892. PubMed ID: 35671850
[TBL] [Abstract][Full Text] [Related]
11. Design and In Vitro Evaluation of Bispecific Complexes and Drug Conjugates of Anticancer Peptide, LyP-1 in Human Breast Cancer.
Timur SS; Bhattarai P; Gürsoy RN; Vural İ; Khaw BA
Pharm Res; 2017 Feb; 34(2):352-364. PubMed ID: 27896591
[TBL] [Abstract][Full Text] [Related]
12. Acid-Sensitive Peptide-Conjugated Doxorubicin Mediates the Lysosomal Pathway of Apoptosis and Reverses Drug Resistance in Breast Cancer.
Sheng Y; Xu J; You Y; Xu F; Chen Y
Mol Pharm; 2015 Jul; 12(7):2217-28. PubMed ID: 26035464
[TBL] [Abstract][Full Text] [Related]
13. Targeted multidrug delivery system to overcome chemoresistance in breast cancer.
Tang Y; Soroush F; Tong Z; Kiani MF; Wang B
Int J Nanomedicine; 2017; 12():671-681. PubMed ID: 28176940
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Anti-Tumor Effect of Folate-Targeted FA-AMA-hyd-DOX Conjugate in a Xenograft Model of Human Breast Cancer.
Liao TT; Han JF; Zhang FY; Na R; Ye WL
Molecules; 2021 Nov; 26(23):. PubMed ID: 34885691
[TBL] [Abstract][Full Text] [Related]
15. Amphiphilic peptide dendritic copolymer-doxorubicin nanoscale conjugate self-assembled to enzyme-responsive anti-cancer agent.
Li N; Li N; Yi Q; Luo K; Guo C; Pan D; Gu Z
Biomaterials; 2014 Nov; 35(35):9529-45. PubMed ID: 25145854
[TBL] [Abstract][Full Text] [Related]
16. DOX-loaded peptide dendritic copolymer nanoparticles for combating multidrug resistance by regulating the lysosomal pathway of apoptosis in breast cancer cells.
Wang J; Li N; Cao L; Gao C; Zhang Y; Shuai Q; Xie J; Luo K; Yang J; Gu Z
J Mater Chem B; 2020 Feb; 8(6):1157-1170. PubMed ID: 31951231
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antitumor activity of a novel pH-activated polymeric drug delivery system for doxorubicin.
Huan M; Zhang B; Teng Z; Cui H; Wang J; Liu X; Xia H; Zhou S; Mei Q
PLoS One; 2012; 7(9):e44116. PubMed ID: 23028490
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific delivery of doxorubicin through conjugation of pH-responsive peptide for overcoming drug resistance in cancer.
Feng C; Rui M; Shen H; Xin Y; Zhang J; Li J; Yue L; Lai W; Xu X
Int J Pharm; 2017 Aug; 528(1-2):322-333. PubMed ID: 28606508
[TBL] [Abstract][Full Text] [Related]
19. Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells.
Kalimuthu K; Lubin BC; Bazylevich A; Gellerman G; Shpilberg O; Luboshits G; Firer MA
J Nanobiotechnology; 2018 Mar; 16(1):34. PubMed ID: 29602308
[TBL] [Abstract][Full Text] [Related]
20. In vitro demonstration of enhanced prostate cancer toxicity: pretargeting with Bombesin bispecific complexes and targeting with polymer-drug-conjugates.
Patil V; Gada K; Panwar R; Majewski S; Tekabe Y; Varvarigou A; Khaw BA
J Drug Target; 2013 Dec; 21(10):1012-21. PubMed ID: 23863118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
